JAK3 and autoimmune disease: Clinical use of STAT5-activating cytokines and growth factors (e.g. IL-2, erythropoetin) is now commonplace and the recent approval of Jak3 inhibitors for the treatment of autoimmune disease and malignancy points to sustained interest in this pathway (Villarino et al., 2015).